The Women's Health Initiative randomized trials showed a reduction in colorectal cancer risk with the use of estrogen plus progesterone (E + P), but not with estrogen alone (E-only), after intervention periods <7 years. Using data from the Cancer Prevention Study II Nutrition Cohort, we examined associations of colorectal cancer risk with E-only and E + P, including analyses by recency and duration of hormone use. During 13.2 years of follow-up, 776 cases of invasive colorectal cancer occurred among 67,412 postmenopausal women participants. Cox proportional hazards models were used to estimate multivariate-adjusted relative risks (RR) and 95% confidence intervals (95% CI) of colorectal cancer for current and former hormone users according to hormone type and duration of use. Relative to women who never used postmenopausal hormones, current, but not former, use of E-only was associated with a reduced risk of colorectal cancer (RR 0.76; 95% CI, 0.59-0.97). Among current E-only users, duration of use was inversely and linearly associated with risk (P trend = 0.01). Use of E-only for <5 years was not associated with reduced risk, whereas use for ≥20 years was associated with a 45% reduction in risk (RR, 0.55; 95% CI, 0.36-0.86). There were no statistically significant associations between E + P and colorectal cancer risk. Our results suggest a strong inverse association of long-term use of E-only with colorectal cancer risk, underscoring the importance of collecting data on duration of hormone use in epidemiologic studies of postmenopausal hormones and risk of disease. (Cancer Epidemiol Biomarkers Prev 2009;18(11):2835-41) 
Introduction
A large and diverse body of epidemiologic, basic, and clinical research suggests an important role of sex hormones in the etiology of colorectal neoplasia. This research includes >27 observational studies, conducted since the 1980s, on the association of postmenopausal hormone use with the risk of colorectal cancer and adenomatous polyps (24) (25) (26) (27) . Based on findings from these observational studies, "ever" use of postmenopausal hormones is associated with a 20% to 40% reduced relative risk (RR) of colorectal cancer (1-3, 6, 8, 9, 11, 13-15, 18, 21, 22) , whereas current or recent use is associated with a 30% to 40% reduced risk (1, 2, 7, 10, 11, 14, 15, 17, 18, 22) . Importantly, several studies (11, 16, 22, 28) observed a statistically significant reduction in risk only after 5 years of hormone use.
A secondary goal of the Women's Health Initiative (WHI) randomized, placebo-controlled, primary prevention trials was to examine the effect of estrogen plus progesterone (E + P; 0.625 mg/d conjugated equine estrogens plus 2.5 mg/d medroxyprogesterone acetate) and estrogen alone (E-only; 0.625 mg/d conjugated equine estrogens) on risk of colorectal cancer. In the E + P trial, after 5.2 years of follow-up, risk of colorectal cancer was reduced among women in the intervention arm relative to placebo [RR, 0.56; 95% confidence interval (95% CI), 0.38-0.81; 112 cases; ref . 29] . In the E-only trial, however, there was no effect of the intervention on colorectal cancer risk (RR, 1.08; 95% CI, 0.75-1.55; 119 cases) during an average of 6.8 years of follow-up (30) . In contrast to the randomized trials, results from the WHI observational study suggested a modest reduction in colorectal cancer risk with E-only use (RR, 0.80; 95% CI, 0.53-1.20; 168 cases) but no reduction in risk with E + P during 7.1 and 5.5 years of follow-up, respectively (31) .
To date, a small number of observational studies have examined the associations of E + P and E-only with colorectal cancer risk, and results from these studies are inconsistent (2, 4, 13, 15, 16, 19, 22, 32, 33) . The Breast Cancer Detection Demonstration Project, the largest prospective study to examine colorectal cancer risk by hormone type, found a nonstatistically significant reduction in risk of colorectal cancer with ever use of E + P and a significant reduction in risk associated with ever use of E-only (13) . The reduced risk for E-only appeared to be attributable to current users and to users with ≥10 years of use, who incurred the strongest reduction in risk (RR, 0.74). However, statistical power to assess the effect of long duration of current hormone use was limited in the Breast Cancer Detection Demonstration Project, which accrued only 40 cases among current E-only users and 32 cases among current E + P users.
Based on these few studies, it seems plausible that risk of colorectal cancer may differ according to the type of hormonal preparation used and the recency and duration of hormone use. The Cancer Prevention Study II (CPS-II) Nutrition Cohort provides an excellent resource for the study of postmenopausal hormone use and risk of colorectal cancer because of its prospective design, duration of follow-up, large sample size, and regularly updated detailed information on hormone use. We therefore examined the associations between risk of incident colorectal cancer and use of postmenopausal hormones by type, recency, and duration of use.
Materials and Methods
Study Population. Study subjects were selected from the 97,786 female participants in the CPS-II Nutrition Cohort, a prospective study of cancer incidence, initiated in 1992 (34) . The ∼184,000 participants in the Nutrition Cohort were selected from 1.2 million participants in CPS-II, a prospective mortality study established by the American Cancer Society in 1982 (35) . Members of the 1982 Cohort, who were ages 50 to 74 years in 1992, were invited to participate in the Nutrition Cohort, as described elsewhere (34) . The Study is approved by the Emory University Institutional Review Board.
At enrollment, participants completed a self-administered questionnaire that included information on demographic, medical, behavioral, environmental, occupational, and dietary factors. Follow-up questionnaires were sent to cohort members in 1997, 1999, 2001, 2003, and 2005 to update exposure information and to ascertain newly diagnosed cancers. The response rate for each of the follow-up questionnaires was ≥89%. For this analysis, the follow-up period ended June 30, 2005 .
Analyses were restricted to postmenopausal women; women who were premenopausal/perimenopausal in 1992, but reported being postmenopausal in 1997 or 1999 (n = 2,658), began contributing person-time to the analysis at that time. Women were excluded based on the following criteria: premenopausal as of 1999, unknown menopausal status or unknown age at menopause (n = 2,520); lost to follow-up (n = 3,152); history of cancer, other than nonmelanoma skin cancer, at enrollment (n = 12,055); unknown type or duration of hormone use (n = 6,472); history of both E-only and E + P use (n = 3,975); use of only oral progesterone or vaginal cream (n = 1,798); reported current use of E + P after hysterectomy (n = 319); nonadenocarcinoma colorectal cancer (n = 15); and report of a colorectal cancer on a first follow-up survey that could not be verified (n = 68). After exclusions, the final analytic cohort consisted of 67,412 postmenopausal women.
Women who developed cancer during the follow-up period, other than colorectal or nonmelanoma skin cancer, were censored at the time of their reported cancer diagnosis. Cohort members with missing hormone data in 1997, 1999, 2001, or 2003 were censored at the time of their missing data report. Subjects who reported an unverifiable colorectal cancer on a later survey (n = 103) were censored on the date of their most recent cancer-free survey. Women who reported changing the type of hormones used (E + P to E-only or vice versa) were censored at the time of the report.
Case Ascertainment. In the analytic cohort, we identified 776 incident colorectal cancer cases diagnosed between enrollment and June 30, 2005 . The majority of cases (n = 641) were first identified by self-report on a follow-up questionnaire and then verified by medical record abstraction or through linkage with state cancer registries when complete medical records could not be obtained (34 Ascertainment of Hormone Use. Information on postmenopausal hormone use was collected at enrollment and on all follow-up questionnaires. Subjects were asked about the type of hormones used, whether hormone use was previous or current, and the duration of use. For this analysis, women were categorized at baseline into mutually exclusive groups of never hormone users (n = 32,916), E-only users (n = 25,437), or E + P users (n = 9,059). Those who were premenopausal/perimenopausal in 1992 were categorized according to their hormone use after they became menopausal and began contributing person-time to the analysis.
Adjustment Variables. Covariates were chosen based on their potential to confound the association between hormone use and colorectal cancer as determined through univariate analyses. Variables included in the final models were body mass index (BMI; 18.5 to <25, 25 to <30, ≥30), smoking (nonsmoker, current, former, smoker with unknown current status), education (high school or less, some college or vocational school, college graduate), race (White, Black, other), physical activity (metabolic equivalents of energy expenditure, quintiles <3.5, 3.5 to <4.5, 4.5 to <14, 14 to <19, ≥19), current use of nonsteroidal anti-inflammatory drugs (NSAID; no, yes), current use of multivitamins (no, <1/d, daily use), family history of colorectal cancer (no, yes), hysterectomy (no, yes), type of menopause (natural, surgical or radiation), red and processed meat intake (g/wk; quintiles), and history of colorectal endoscopy (never received endoscopy test, received test). Age at menopause, age at menarche, age at first live birth, parity, oral contraceptive use, vegetable intake, total calcium intake, energy intake, and alcohol use were found to have no appreciable influence (<2% change) on the RRs of colorectal cancer associated with hormone use.
Statistical Analysis. Age-adjusted and multivariateadjusted RRs and 95% CIs were estimated using Cox proportional hazards models, stratified on age at enrollment (38) . RRs reported in the text are multivariate-adjusted. All covariates were modeled using status at enrollment, except colorectal endoscopy, which was modeled as a time-dependent variable.
Postmenopausal hormone use was modeled as a time-dependent variable. At the start of each interval, defined by completion of a new questionnaire, each woman's hormone use was updated. Women who reported never having used postmenopausal hormones were categorized as never users. Women who reported current or past use of either E-only or E + P were categorized as either current or former users, and their total lifetime duration of use as of the start of that follow-up interval was calculated. For current users of E-only, total duration of use was classified as <5, 5 to <10, 10 to <15, 15 to <20, or ≥20 years. For current users of E + P, total duration of use was classified as <5, 5 to <10, or ≥10 years. Former Eonly users were classified as <5 or ≥5 years, and former E + P users were left in a single category due to small numbers of users with ≥5 years use. P values for linear trend were generated by the likelihood ratio test statistic from models of years of hormone use as a continuous variable. Women who reported changing from never use to use of E + P or E-only were recategorized into the appropriate hormone use category. We examined whether the association between current postmenopausal hormone use and risk of colorectal cancer varied by BMI (18.5 to <25, 25 to <30, ≥30) and age (<70, ≥70 years) and evaluated effect modification by modeling multiplicative interaction terms for current use of each hormone type. P values for interactions were generated by the likelihood ratio test statistic that compared a multivariate-adjusted model with only the main effects to a model that contained the main effects and interaction terms.
To examine whether the association with risk of colorectal cancer was statistically different for current E-only than for current E + P, we compared our main multivariate-adjusted model containing separate variables for current E-only and current E + P to a model that contained a single variable for current hormone use without differentiation by type. A P value for heterogeneity of effects by hormone type was then generated by a likelihood ratio test with 1 df.
Results
At baseline, 48.8% of women had never used postmenopausal hormones, 21.7% were current E-only users, 10.6% were current E + P users, 16.1% were former E-only users, and 2.8% were former E + P users (Table 1 ). E + P users reported higher education and lower red meat intake and were more often former smokers than never users or E-only users. E-only users were more likely to have had surgical or radiation-induced menopause. Average age at study entry in 1992 was lowest among current E + P users and highest among former E-only users, likely reflecting temporal trends in use of these different hormonal preparations (39) . Current use of E-only was associated with reduced risk of colorectal cancer compared with never use (RR, 0.76; 95% CI, 0.59-0.97), whereas former use was not (Table 2) . No statistically significant associations were observed with current or former use of E + P. Although the RR estimates differed between current E-only and current E + P, statistical heterogeneity was not evident (P = 0.27).
Among current E-only users, colorectal cancer risk was inversely and linearly associated with duration of use (P trend = 0.01; Table 3 ). Current use of E-only for <5 years was not associated with risk (RR, 1.13), whereas use of E-only for ≥20 years was associated with a substantial reduction in colorectal cancer risk (RR, 0.55). This trend of decreasing risk after 5 years of E-only use persisted in subsite analyses of colon cancer (P trend = 0.01), particularly for tumors in the proximal colon (P trend = 0.007). There was no clear trend with duration of E-only use for risk of cancer in the distal colon or rectum, although numbers were smaller. RRs for current E + P use were near unity, even for long-duration use. The RRs of former users did not vary by duration (data not presented).
No significant effect modification was found when results were stratified by BMI or attained age (Table 4) . The slightly stronger association of E-only use among older women likely reflects their longer average duration of hormone use, which was 18.3 years, as opposed to 11.3 years in the younger women. When results were adjusted for duration, the statistical evidence for an interaction between current E-only use and age was weakened (P = 0.56). The RRs for E + P use were similar between younger and older women.
To evaluate the robustness of our E-only results, we performed a series of sensitivity analyses. Because the biological effects of dermal hormone patches may differ from those of oral hormones, we excluded or censored person-time from 2,958 women who reported patch use, and the results remained similar to those of the main analysis (current E-only use, RR, 0.76; 95% CI, 0.59-0.98). Results also remained similar when analyses were restricted to women who had undergone hysterectomy (current E-only use, RR, 0.79; 95% CI, 0.57-1.09). Furthermore, the association with current use of E-only persisted when covariates, BMI, smoking, physical activity, use of NSAIDs, multivitamins, family history of colorectal cancer, and hysterectomy, were modeled as time-dependent variables and updated with each follow-up survey (RR, 0.77; 95% CI, 0.60-0.99).
Finally, to compare our observational results for E-only with the E-only WHI trial, which had an average length of follow-up of 6.8 years, we examined the colorectal cancer risk associated with current E-only use for <7 years and found no association (RR, 0.99; 95% CI, 0.69-1.43).
Discussion
In this large longitudinal cohort study, current E-only use was associated with a statistically significant lower risk of colorectal cancer, and the association was stronger with increasing duration of use. Although E + P was not associated with colorectal cancer in our study, a reduction in risk similar to that observed with E-only could not be ruled out. Results of other prospective studies that have examined E-only versus E + P are inconsistent. A statistically significant reduction in colorectal cancer risk with E-only, but not E + P, was observed in the Breast Cancer Detection Demonstration Project cohort (13) , but the opposite result was observed in a population-based U.K. cohort (32, 33) . Results of case-control studies are Adjusted for age at 1992 survey, time-dependent colorectal cancer endoscopy screening, smoking, education, race, physical activity, use of NSAIDs, use of multivitamins, red meat intake, family history of colorectal cancer, hysterectomy, and type of menopause (models stratified by attained age also adjusted for BMI).
also conflicting (2, 15, 16, 22) , with two supporting a stronger colorectal cancer risk reduction for E-only than E + P (2, 22) . A nonsignificant 20% reduction in risk for E-only was found in the WHI observational study, but none was found for E + P (31). Our findings for E-only appear to differ from those of the WHI randomized trials, which suggested that E-only use was not associated with risk of colorectal cancer (30) . One possible reason for this apparent discrepancy is the relatively short intervention period of the WHI E-only trial. Consistent with the relatively short duration of the WHI E-only intervention, current E-only use for <7 years in this study was not associated with risk of colorectal cancer. The risk reduction from E-only use in this study was driven, quite largely, by long-duration use. Collectively, our results, and those of other studies (11, 16, 22, 28) , suggest that ≥5 years of hormone use is required to reduce risk of colorectal cancer.
Several other studies noted stronger colorectal cancer risk reductions with hormone use among older than younger women (11, 14, 22, 24, 26) . The RR estimates for E-only were lower among older than younger women in our study as well. However, this difference was not statistically significant and appeared to be at least partly attributable to longer duration of use among the older women.
Exogenous estrogen has been hypothesized to have a greater effect on modifying risk of colorectal cancer among women with a low BMI due to the lower endogenous levels of estrogen among lean women (40) . Although studies that have evaluated this potential effect modification have been equivocal (14-16, 25, 26, 41) , in general, and consistent with our findings, the majority of studies suggest that the influence of estrogens on colorectal cancer risk is not dependent on BMI status.
Our study has several notable strengths: it is one of the largest to date, allowing reasonable statistical power for subgroup analyses; its prospective design eliminates the bias due to differential recall of hormone use. Because of the availability of detailed, regularly updated information about hormone use, we were able to characterize mutually exclusive groups of E-only users, E + P users, and nonhormone users, thus reducing misclassification. In addition, we were able to control for colorectal endoscopy screening in a time-dependent manner, reducing the potential for confounding due to differential screening practices among hormone users and nonusers. A limitation of this study is that hormone use was self-reported, although self-reported hormone use has been shown to be in good agreement with physician records (42) . Our ability to precisely estimate the risk associated with long-duration E + P use was also limited by the relatively small numbers of long-term E + P users in our cohort. Our study participants were predominantly White, middle-aged or elderly, and well-educated; therefore, results may not be generalizable to populations with different characteristics.
The biological mechanisms responsible for the inverse association with E-only are unclear, but there is evidence to suggest that estrogens may specifically reduce risk of tumors with microsatellite instability (43) . Microsatellite instability may often occur as a result of methylation in a specific mismatch repair gene, MLH1. Studies (44, 45) suggest that preventing age-related methylation, perhaps of the estrogen receptor or one of the mismatch repair genes (e.g., MLH1), may be an important mechanism through which estrogens exert a protective effect in the colon and thereby decrease risk of microsatellite instability tumors. Because we do not have tumor samples, however, we cannot address this issue directly.
Our results, based on a large prospective study of women with regularly updated exposure information, suggest that long-term use of E-only reduces risk of colorectal cancer. A reduction in risk for E + P was not observed in these data yet could not be ruled out. The prevalence of menopausal hormone use peaked in 1999 and then declined dramatically in the United States following the 2002 publication of results from the WHI trials (39) . Given evidence from randomized trials that the risks associated with hormone use likely outweigh the benefits, our finding of a potential benefit for colorectal cancer risk should not appreciably influence current clinical practice. Nevertheless, our study underscores the importance of continued follow-up of the WHI and prospectively followed cohorts with detailed information on lifetime hormone use to gain a better understanding of the long-term effects of exogenous hormones on disease risks.
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